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SObjective: The presence of ectopic thymic tissue has been considered one of the most significant predictors of
poor outcome after thymectomy for myasthenia gravis, but the role of active ectopic tissue is unknown. The
current study analyzed the importance of this factor on post-thymectomy outcome of patients with class III
myasthenia gravis.
Methods:We retrospectively reviewed 106 patients with class III, anti-acetylcholine receptor antibody-positive,
nonthymomatous myasthenia gravis (70 female, 36 male; mean age, 41 17 years) who underwent transsternal
extended thymectomy between 1980 and 2005. Quality of life was assessed from 1996 with the Short Form 36
questionnaire. Prognosticators were investigated using complete stable remission and normalized component
summaries as end points.
Results:Major morbidity rate was 5%with no perioperative mortality. Ectopic thymic tissue was detected in 51
patients (48%), 34 of whom (67%) presented germinal centers. Complete follow-up was available in 96 patients
(mean 160  91 months). Fifty-two patients (54%) achieved complete stable remission, and 20 patients (21%)
presented clinical and pharmacologic improvement. Lack of postoperative improvement in physical and psycho-
social domains was significantly correlated with active ectopic thymus. At Kaplan–Meier evaluation, duration of
symptoms (>12 months) (P ¼ .04), oropharyngeal involvement (P ¼ .02), germinal centers (P ¼ .03), ectopic
thymus (P¼ .001), and active ectopic thymus (P<.0001) were negative predictors of complete stable remission.
The presence of active ectopic thymus was the most significant negative predictor of complete stable remission
at Cox regression (P ¼ .03).
Conclusions: Extended thymectomy yields good outcome in patients with nonthymomatous class IIImyasthenia
gravis. The presence of active ectopic thymus was the most significant predictor of poor outcome. These patients
should be rigorously followed and undergo early aggressive therapy. (J Thorac Cardiovasc Surg 2012;143:601-6)The removal of as much thymic tissue as possible is consid-
ered one of the key points for predicting complete stable re-
mission (CSR) of nonthymomatous myasthenia gravis
(MG).1-7 The persistence of ectopic thymic tissue8-11 is
deemed as one of the main reasons of poor outcome after
thymectomy.12,13 Furthermore, the presence of germinal
centers in the thymus has reported to be a source of
antibodies against acetylcholine receptors (anti-AchR Ab)
and another significant negative prognostic factor.12,13
We hypothesized that the histologic evidence of active
tissue in both native and ectopic thymus could predispose
to the failure of a symptomatologic response to thymec-
tomy. The purpose of our retrospective study was to analyze
the most significant predictor of poor outcome aftere Department of Thoracic Surgery, Multidisciplinary Myasthenia Gravis
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The Journal of Thoracic and Cathymectomy in class III nonthymomatous MG, with special
attention to the presence of germinal centers in heterotopic
thymus.PATIENTS AND METHODS
Patients
Of a total of 194 myasthenic patients who underwent transsternal ex-
tended thymectomy at Tor Vergata University between 1980 and 2005,
we retrospectively reviewed 106 patients affected with nonthymomatous,
anti-AchRAb–positive, class IIIMG (Figure 1). According to theMyasthe-
nia Gravis Foundation of America (MGFA), class III was identified as
a moderate weakness predominantly affecting limb or axial muscles (type
a) or oropharyngeal muscles (type b).14 Patients operated before 2000 and
therefore classified according to the Osserman’s classification15 were retro-
spectively reclassified.We restricted the study only to this class because it is
themost common and fittest to detect significant quality of life changes.We
also excluded patients operated after 2005 to have a minimum follow-up of
at least 5 years. Patient population consisted of 70 female and 36 male sub-
jects aged 15 to 74 years (mean, 41.1  16.6 years). Further demographic
data are summarized in Table 1. Permission for activating the entire project,
including the use ofmedical records and specimen reanalysis, was issued by
the internal review board of Tor Vergata University. Each patient released
written and fully informed consent to the use of personal data.
The diagnosis of MGwas based on clinical features and 1 or more of the
following criteria: response to edrophonium chloride, positive electromy-
ography, and demonstration of circulating anti-AchR Ab. A quantitative
MG score16 from 0 (no impairment) to 39 (maximum impairment) was
also evaluated pre- and postoperatively.rdiovascular Surgery c Volume 143, Number 3 601
FIGURE 1. Diagram indicating patient’s selection. Pts, Patients; MG,
myasthenia gravis; Ach-RAb, acetylcholine receptor antibodies.
Abbreviations and Acronyms
anti-AchR Ab ¼ antibodies against acetylcholine
receptors
CI ¼ confidence interval
CSR ¼ complete stable remission
MCS ¼ mental component summary
MG ¼ myasthenia gravis
MGFA ¼ Myasthenia Gravis Foundation
of America
PCS ¼ physical component summary
SF-36 ¼ Short Form 36
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alone or in combination with steroids (n ¼ 28). Only 5 patients were also
taking azathioprine. A medical panel composed of neurologists, thoracic
surgeons, and anesthesiologists discussed the decision and timing for thy-
mectomy. Each patient was clinically stable before surgery. In the presence
of increasing weakness or bulbar symptoms, plasmapheresis (n¼ 17) or in-
travenous immunoglobulins (n ¼ 27) were administrated before surgery.
Surgical Technique
We consider thymectomy extended according to Sonnet and Jaretzki.17
The operation was accomplished under general anesthesia with single-lung
ventilation. Only short-acting, nondepolarizing neuromuscular relaxants
were occasionally used. During the operation and 12 hours after, oral pyr-
idostigmine was administered through a nasogastric tube. Resection rou-
tinely included areas more frequently the site of ectopic thymic tissue,2
such as perithymic fat tissue from anterior mediastinum, neck, aortocaval
groove, aortopulmonary window, retroinnominate space, and both cardio-
phrenic angles.
At the end of the operation, we encouraged early extubation and phys-
iotherapy. Pain control was preferably restricted to oral analgesics.
Thymic Specimen Evaluation
All excised tissue was routinely examined. Hematoxylin and eosin–
stained sections were prepared from paraffin-embedded blocks and ex-
amined under low magnification (320). Where histologic data were
missing, the specimens were reprocessed by retrieving them from archive
material.
Ectopic thymus was researched by randomly taking 1 from every 5 sec-
tions of fat tissue inclusion collected during thymectomy. The presence of
the germinal centers was researched by examining visual fields of at least 5
sections of the thymus. Monoclonal antibodies against CD23 were used to
demonstrate the presence of germinal centers. Briefly, sections from each
specimen were cut at 3 to 5 mm, mounted on glass, and dried overnight
at 37C. All sections were then deparaffinized in xylene, rehydrated
through a graded alcohol series, and washed in phosphate-buffered saline.
This buffer was used for all subsequent washes and for dilution of the an-
tibodies. Tissue sections were heated twice in a microwave oven for 5 min-
utes each time at 700W in citrate buffer (pH 6) and then processed with the
standard streptavidin-biotin-immunoperoxidase method. Mouse monoclo-
nal anti-human antibodies specific for CD23 (clone 1B12, Novocastra, UK)
were used at a 1:100 dilution. All the primary antibodies were incubated for
1 hour at room temperature. Diaminobenzidine was used as the final chro-
mogen, and hematoxylin was used as the nuclear counterstain. Negative
controls for each tissue section were performed leaving out the primary an-
tibody. Cytoplasmic staining with anti-human CD23 was scored as positive
by an experienced pathologist.602 The Journal of Thoracic and Cardiovascular SurgPostoperative Evaluation
Clinical outcome was always assessed according to the MGFA post-
intervention status classification14 during a multidisciplinary follow-up
session. CSR was defined as no symptoms or sign of MG at careful exam-
ination for at least 1 year in the absence of therapy during that time.14
Since 1996, quality of life changes after surgery were measured by the
Medical Outcomes Study Short Form 36 (SF-36) self-administered ques-
tionnaire.18 The SF-36 consists of 36 multiple-choice questions covering
8 health concepts: physical functioning, social functioning, physical role,
emotional role, vitality, body pain, mental health, and general health per-
ception (best score¼ 100, worst¼ 0). From these values, it is also possible
to calculate a unique score for the physical component summary (PCS) and
the mental component summary (MCS) (Health Assessment Laboratory,
New England Medical Center, Boston, Mass, 1994). We repeated the
same preoperative evaluations 6 months after thymectomy and then every
12 months after.
Statistical Analysis
We presented values of descriptive variables as mean  standard devi-
ation. All analyses were performed with the Statistical Package for the So-
cial Sciences (SPSS Inc, Chicago, Ill). The interdependence between
prognostic factors and end points was tested by the 2-tailed chi-square
test. End points were the improved postintervention status, normalized
(50) PCS values, and normalized (50) MCS values. Significant vari-
ables were then analyzed with logistic regression. Correlations between
continuous variables were analyzed by the Spearman test.
CSR survival was determined by the Kaplan–Meier method. Time to
CSR was defined as the time between the day of surgery and the date of
CSR. Patients who had not achieved CSR were censored with time toery c March 2012
FIGURE 2. Distribution of ectopic thymic tissue and relative frequencies
in a total population of 106 patients.
TABLE 1. Clinical features of patients undergoing thymectomy for
class III myasthenia gravis
Clinical features Value
Age (mean  SD, y) 41  17
Early onset (40 vs>40 y) 72 vs 34
Sex (male vs female) 36:70
Symptom duration (mean  SD, mo) 18  7
Oropharyngeal symptoms (no. patients%) 29 (27%)
Preoperative MG score (0–39) (mean  SD) 21  4
Preoperative anti-AchR Ab (mean  SD nmol/L) 71  65*
Preoperative anticholinesterase dosage (mean  SD mg/d) 201  80*
Preoperative steroids use (no. patients%) 27 (25%)
Hospital stay (mean  SD, d) 6.1  4.1
Follow-up (mean  SD, mo) 160  91
1-y improvementþ remission (no. patients%) 15 (14%)
1-y anti-AchR Ab (mean  SD nmol/L)y 15.5  5.2
1-y MGFA class (mean  SD) 1.9  1.0
1-y anticholinesterase dosage (mean  SD mg/d) 134  56
1-y MG score (0–39) (mean  SD) 18  5
Crude CSR rate (no. patients%)* 52 (54%)
5-y improvementþ remission (no. patients%)* 51 (53%)
5-y MGFA class (mean  SD)* 1.4  0.8
5-y MG score (0–39) (mean  SD)* 16  6
10-y improvementþ remission (no. patients%)* 63 (66%)
10-y MGFA class (mean  SD)* 1.2  0.5
10-y MG score (0–39) (mean  SD)* 14  8
SD, Standard deviation;MG,myasthenia gravisanti; anti-AchR Ab, antibodies against
acetylcholine receptors; MGFA, Myasthenia Gravis Foundation of America; CSR,
complete stable remission. *Ninety-six patients who completed follow-up; 10 pa-
tients were lost. yFifty-one patients available.
Ambrogi and Mineo General Thoracic Surgery
G
T
SCSR considered from operation to the most recent follow-up. Univariate
analysis was performed by the log-rank test. Significant variables were sub-
sequently analyzed by Cox regression.
RESULTS
Operative Results
The main clinical features are summarized in Table 1.
There was no perioperative mortality, and the major mor-
bidity rate was 5% with sternal wound infection (n ¼ 2),
pneumonia and pleural effusion (n ¼ 2), and permanent
phrenic nerve injury (n ¼ 1).
Histologic Findings
Histologic examination showed hyperplasia in 64 pa-
tients (60%), normal thymus in 36 patients (34%), and
atrophic thymus in 6 patients (6%). The presence of germi-
nal centers was detected in 43 native thymuses (41%): 26
(26/64, 41%) with hyperplastic and 17 (17/42, 47%) with
normal or atrophic histology. Heterotopic thymic tissue
was found in 51 patients (48%) and was more frequent in
association with atrophic histology (6/6, 100%) than in
the normal (19/36, 53%) or hyperplastic (26/64, 41%) na-
tive thymus. Location and frequencies are reported in
Figure 2. Twenty-six patients had ectopic thymic tissue at
2 different sites, and 19 of those presented germinal centers
in both foci. The presence of germinal centers in ectopicThe Journal of Thoracic and Cathymus was proved in 34 patients (34/51, 67%) and,
namely, in all those with atrophic thymus.Long-Term Quality of Life Results
Quality of life changes were available for 59 patients
(Table 2). All domains except body pain significantly im-
proved with time, up to a maximum of 10 years. At baseline,
PCS values were more compromised in the presence of sole
skeletal muscle involvement (40 12 vs 50 12, P¼ .04).
On the other hand, MCS was significantly decreased (37 
14 vs 51  11, P ¼ .004) in patients with oropharyngeal
symptoms. Postoperatively, there was a significant correla-
tion of MG quantitative score with both PCS and MCS
(Table 2).
SF-36 PCS and MCS stably achieved the end point value
in approximately one quarter of the patients, and this rate
continued to improve with time (Table 2). There was signif-
icant interdependence between the PCS (P<.0001) or MCS
(P¼ .001) and the CSR. Both PCS and MCS normalization
were significantly correlated with the absence of ectopic
thymic tissue (P ¼ .03 and .01, respectively), and PCS nor-
malization was significantly correlated with the absence of
active ectopic thymic tissue (P ¼ .0001) (Table 3).Long-Term Complete Stable Remission Results
Complete follow-up was available in 96 patients with
a mean length of 160  91 months (range 60–256 months).
Five patients died, but only 2 of them died of causes directly
related to MG.
Fifty-two patients (54%) achieved CSR, and 20 patients
(21%) presented clinical and pharmacologic improvement.
Quantitative MG score significantly improved at 5 yearsrdiovascular Surgery c Volume 143, Number 3 603
TABLE 2. Mean ± standard deviation changes of Short Form 36 domains and relationship with symptoms
SF-36 domains Baseline 1 y 2 y 3 y 5 y 10 y
No. patients 59 56 48 41 32 13
Physical function (0–100) 55  12 58  13 60  10* 64  15y 71  20z 68  17z
Role physical (0–100) 35  9 38  12 43  11* 49  10y 54  21z 51  21z
Body pain (0–100) 85  18 67  19* 70  19 74  15 77  11 73  10
General health (0–100) 50  14 54  14 57  11* 59  10y 63  15y 60  18y
Vitality (0–100) 47  10 50  10 52  10* 55  16* 58  9y 56  13y
Social function (0–100) 70  11 71  11 75  10* 78  12y 81  14y 75  10y
Role emotional (0–100) 46  12 51  10* 58  9y 66  11z 74  18z 76  22z
Mental health (0–100) 70  9 72  11 73  9 74  8* 74  10* 74  19*
PCS (0–70) 43  9 44  9 45  8* 47  10* 48  7* 47  9*
MCS (0–70) 47  7 48  14 49  10 50  17* 50  13* 50  10*
PCS  50 (no. patients%) 13 (22%) 14 (25%) 14 (29%) 14 (34%) 14 (43%) 8 (61%)
MCS  50 (no. patients%) 16 (28%) 17 (30%) 17 (35%) 16 (39%) 16 (50%) 8 (61%)
Quantitative MG score (0–39) 21  4 18  5 18  4 17  4 16  6* 14  8y
Spearman PCS vs MG score (rho) 0.30* 0.39* 0.45y 0.48y 0.48y 0.56y
Spearman MCS vs MG score (rho) 0.16 0.21 0.28* 0.33* 0.39* 0.50y
PCS, Physical component summary; MCS, mental component summary; MG, myasthenia gravis; SF-36, Short Form 36. *P<.05. yP<.01. zP<.001.
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sponse to thymectomy is summarized in Table 3.
The global improvement rate according to the
symptomatic-medication response increased from 14% at
1 year to 53% at 5 years and 66% at 10 years, respectively
(Table 1). CSR survivalwas 21% and 47% at 5 and 10 years,
respectively. The median time from thymectomy to CSR
was 88 months, ranging from 11 to 154 months. There was
no significant association between CSR rate at 24 monthsTABLE 3. Univariate analysis of factors influencing response to thymecto
Postintervention status
Improved Unchanged or worsened
Sex
Male 19 11
Female 53 13
Symptom duration
<12 mo 15 10
12 mo 57 14
Oropharyngeal involvement
Yes 15 11
No 57 13
Histology
Hyperplasia 57 4
Normal 15 14
Involuted - 6
Germinal centers
No 46 9
Yes 26 15
Ectopic thymic tissue
No 41 6
Yes 31 18
Ectopic active tissue
No 16 1
Yes 15 17
PCS, Physical component summary; MCS, mental component summary.
604 The Journal of Thoracic and Cardiovascular Surgand sex (P¼ .36), age (<40 vs40 years) (P¼ .42), preop-
erative use of corticosteroids (P¼ .07), preoperative histol-
ogy (hyperplastic vs normal-atrophic) (P ¼ .07) or
plasmapheresis (P¼ .11), and need of postoperative intuba-
tion (P¼ .33). On the other hand, shorter duration of disease
(<12 months) (P ¼ .04), oropharyngeal involvement
(P ¼ .02), presence of germinal centers in native or ectopic
thymus (P¼ .03), and presence of ectopic thymus (P¼ .001)
(Figure 3) were negative predictors. The presence ofmy (chi-square test)
P value
PCS
P value
MCS
P value50 <50 50 <50
.08 4 12 .65 7 9 .27
10 22 9 23
.04 4 17 .17 5 16 .21
10 17 11 16
.01 4 12 .65 3 10 .14
10 22 13 22
.06 10 21 .60 13 18 .19
4 11 3 12
0 2 0 2
.02 4 15 .31 5 14 .40
10 19 11 18
.01 3 19 .03 3 19 .01
11 15 13 13
.001 2 14 .0001 5 10 .05
9 1 8 3
ery c March 2012
FIGURE 3. Cumulative complete remission Kaplan–Meier curve for the
presence of ectopic thymic tissue (A) and germinal centers (B).
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tor of lack of CSR (P>.0001).Multivariate Analysis
At logistic regression, all end points were significantly
influenced by the presence of ectopic thymic tissue: CSR
exp B ¼ 5.8 (95% confidence interval [CI], 1.7–19.8;
P ¼ .005), PCS exp B ¼ 4.6 (95% CI, 1.1–19.7;
P ¼ .03), MCS exp B ¼ 6.3 (95% CI, 1.5–26.7; P ¼ .01).
At Cox regression analysis, the presence of active ectopic
thymic tissue (P ¼ .03; odds ratio, 0.9; 95% CI, 0.1–1.7)
was selected as the most significant negative CSR
prognosticator.COMMENT
Thymectomy is considered an integrated step in the treat-
ment of anti-Ach-R Ab–positive MG.2,3 The site of anti-
AchR Ab production is likely located in the activated areas
(ie, B-cell follicles and germinal centers) of thymic tis-
sue.12,13,19,20 Thus, the removal of as much thymic tissueThe Journal of Thoracic and Caas possible is considered the mainstay for a successful
thymectomy.5,21
However, thymic tissue can also be present in heterotopic
adjacent islets,8-11 and their persistence is considered one of
the main reasons of scant symptomatic improvement after
thymectomy.12,13 Our series claimed some interesting
points concerning the prognostic role of ectopic thymic
tissue.
First, the presence of ectopic tissue is a relatively frequent
finding during thymic surgery.8-11 We evidenced ectopic
thymic tissue in approximately half of the patients; it was
found anywhere in the anterior mediastinum, in the lower
cervical area, and even in the middle mediastinum
(Figure 2). Therefore, routine and complete removal of these
compartments is deemed necessary tomaximize outcome as
proposed by Jaretzki and Wolff.5
Second, despite the intention to achieve an extended sur-
gical resection, we showed that the probability of leaving
further residual foci is high. We postulate that the presence
of heterotopic thymus is evidence of diffuse thymic spread
in the thoracic-cervical regions. The possibility of a com-
plete thymectomy seems to be a ‘‘chimera.’’ However, in
these instances, extended thymectomy might be performed
for prognostic purposes or with a cytoreductive intent aimed
at decreasing the antibody burden.
Third, we found that the presence of ectopic and mainly
active tissue is more frequent in the case of an atrophic or
normal thymus. This finding could justify the onset of
anti-AchR Ab–positive MG even in patients with involuted
and apparently ‘‘silent’’ thymus.22
Finally, we demonstrated that the discovery of ectopic
thymus was the most significant predictor of poor response
at multivariate analysis. This effect was enhanced by the
presence of germinal centers. The poor response included
both CSR and physical and psychosocial quality of life do-
mains. Patients who present these features at histologic ex-
amination should be included in a different clinical pathway
with stricter follow-up and a more aggressive therapeutic
regimen based on immunosuppressive drugs, eventually
leading to a reoperation.
The thymic germinal center is where B-lymphocytes dif-
ferentiate to produce antibodies with high affinity toward
antigens. Several studies hypothesized the production of
anti-AchRAb from the thymus, suggestingacritical roleof the
thymic germinal centers in the pathogenesis of MG.4,13,19
The correlation between the presence of germinal centers,
especially if located in ectopic tissue, and the poor outcome
of thymectomy reinforces this hypothesis.12
We also observed that extended thymectomy may have
a significant impact on quality of life. Nonthymomatous thy-
mectomy can achieve significant improvement in both phys-
ical and psychosocial domains, which are particularly altered
in MGFA class III. This positive effect can progressively in-
crease over time. Previous studies concerning quality of liferdiovascular Surgery c Volume 143, Number 3 605
General Thoracic Surgery Ambrogi and Mineo
G
T
Sindifferently included thymomatous and nonthymomatous
cause.3,23 The lack of this discrimination may have some
relevance in the evaluation of quality of life parameters,
because thymomatous forms may have a more severe
impairment because of adjuvant antineoplastic therapies
and stricter controls. For these reasons, a comparison with
previous studies may be unfair.Study Limitations
Several limitations of this study deserve mention. The
major limitation is represented by its retrospective nature.
Another limitation is represented by the wide time span re-
quired to gather a consistent sample size, which implies ob-
vious differences in diagnostic and therapeutic strategies
due to scientific and technologic advancements. Finally,
data on quality of life are available for only one half of
the study population. Despite these limitations, the study
provides valuable data based on a long-experienced single
surgeon always performing an intentional extended
thymectomy.CONCLUSIONS
Extended thymectomy, when properly performed for
both timing and extension, yields a satisfactory long-term
outcome and quality of life in patients with nonthymoma-
tous, anti-AchR Ab–positive, class III MG. Thymectomy
is a mandatory step in a more accurate determination of
the prognosis of the disease. The presence of active ectopic
thymic tissue seems to be the most significant predictor of
poor response to thymectomy. This finding should be useful
to address these patients to a more rigorous follow-up and
aggressive therapeutic regimen.
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